InvestorsHub Logo
Followers 2544
Posts 250729
Boards Moderated 34
Alias Born 05/06/2014

Re: None

Tuesday, 05/23/2017 12:35:07 AM

Tuesday, May 23, 2017 12:35:07 AM

Post# of 90702
$PMCB PharmaCyte Biotech Pays Tribute to National Cancer Research Month PMCB

PharmaCyte Biotech is proud to honor May as National Cancer Research Month.

In 2007, and again in 2011, the United States Congress declared the month of May as National Cancer Research Month to acknowledge the importance of cancer research and the contributions of researchers, doctors, patients and advocates who are dedicated to conquering cancer.
PharmaCyte Biotech is a leader among start-up biotech companies when it comes to developing new and innovative ways to treat cancer. PharmaCyte’s cancer therapy development pipeline, featuring its transformative platform technology, Cell-in-a-Box®, includes:

* Encapsulated live cells converting ifosfamide in the targeted treatment of pancreas cancer. Preparations are currently underway to submit an Investigational New Drug (IND) application to the FDA to commence a pivotal human clinical trial.

* Encapsulated live cells converting ifosfamide to delay malignant ascites fluid accumulation. Preclinical studies are ongoing.

* Encapsulated live cells converting cannabinoid prodrugs to treat solid tumor cancers, initially brain cancer. Preclinical studies are ongoing.

Cancer is a term that collectively describes over 200 diseases. The control of cancer involves a combination of both prevention and treatment. Treatment requires an understanding of cancer at cellular and molecular levels, the development of drugs that affect specific targets and validation of efficacy through clinical studies.
According to the National Cancer Institute, in 2016, approximately 1.7 million new cases of cancer were diagnosed in the United States, and nearly 600,000 people died from the disease. The most common solid tumor cancers include cancers of the breast, lung, prostate, colon, bladder, skin, thyroid, kidney, endometrium and pancreas.
On a positive note, thanks to both research and prevention efforts, the overall death rate from cancer has slowly declined since the early 1990s. In the last 10 years, overall cancer death rates have dropped about 1%-2%, although death rates for a few cancers have remained stable or even increased.
According to the American Cancer Society, the greatest barriers to moving cancer research forward are lack of money, resources and recruiting clinical trial participants. Regulatory hurdles are another barrier. Through increased awareness, regulatory improvements and the tireless efforts of countless individuals, hopefully these barriers may be overcome.

http://pharmacyte.com/pharmacyte-biotech-pays-tribute-national-cancer-research-month/

investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.